Posted by Michael Wonder on 16 Dec 2021
COVID-19: EMA recommends authorisation of antibody medicine Xevudy
16 December 2021 - EMA’s CHMP has recommended authorising the monoclonal antibody Xevudy (sotrovimab) for the treatment of COVID-19.
The Committee recommended authorising Xevudy for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.
